<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621633</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B2203</org_study_id>
    <secondary_id>2012-000983-27</secondary_id>
    <nct_id>NCT01621633</nct_id>
  </id_info>
  <brief_title>A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers</brief_title>
  <official_title>A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to characterize the pharmacokinetics as well as safety and tolerability of a
      single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment
      compared to matched healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</measure>
    <time_frame>From pre-dose on Day 1 until 96h post-dose (Day 5)</time_frame>
    <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUCinf)] of LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</measure>
    <time_frame>From pre-dose on Day 1 until 96h post-dose (Day 5)</time_frame>
    <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</measure>
    <time_frame>From pre-dose on Day 1 until 96h post-dose (Day 5)</time_frame>
    <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Serious Adverse Events and Death</measure>
    <time_frame>From the screening visit until Day 5</time_frame>
    <description>Adverse events, serious adverse events and death were monitored from screening to end of study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1: mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg, given as a single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg, given as a single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <arm_group_label>Group 1: mild hepatic impairment</arm_group_label>
    <arm_group_label>Group 2: moderate hepatic impairment</arm_group_label>
    <arm_group_label>Group 3: healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects:

               -  Male and female subjects aged 18-75 years.

               -  Body weight at least 55 kg with a body mass index between 18-35 kg/m2.

          -  Hepatic impairment subjects:

               -  Mild or moderate hepatic impairment.

        Exclusion Criteria:

          -  All subjects:

               -  Clinical manifestations of postural symptomatic hypotension at screening or
                  baseline.

               -  History of hypersensitivity to LCZ696 or to drugs of similar classes.

          -  Hepatic impairment subjects:

               -  Hepatic impairment due to non-liver disease.

               -  Treatment with any vasodilator, autonomic alpha blocker or beta2 agonist within 2
                  weeks of dosing.

               -  Encephalopathyy Stage III or IV.

               -  Primary biliary liver cirrhosis or biliary obstruction.

               -  History of gastro-intestinal bleeding within 3 months prior to screening.

          -  Healthy subjects:

               -  Any surgical or medical condition which might significantly alter the
                  distribution, or excretion of drugs, or which may jeopardize the subject in case
                  of participation in the study.

               -  Use of prescription drugs, herbal supplements, and/or over-the-counter
                  medication, dietary supplements (vitamins included) within 2 weeks prior to
                  initial dosing.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grunstadt</city>
        <zip>D-67269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <results_first_submitted>July 11, 2015</results_first_submitted>
  <results_first_submitted_qc>July 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2015</results_first_posted>
  <last_update_submitted>July 11, 2015</last_update_submitted>
  <last_update_submitted_qc>July 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants received the study treatment according to the population subset that was defined based on the severity of hepatic impairment and healthy volunteers: Group 1, subjects with mild hepatic impairment; Group 2, subjects with moderate hepatic impairment; Groups 3 and 4, healthy volunteers matching to Groups 1 and 2, respectively.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants With Mild Hepatic Impairment (HI)</title>
          <description>LCZ696 200 mg, given as a single oral dose</description>
        </group>
        <group group_id="P2">
          <title>Participants With Moderate Hepatic Impairment (HI)</title>
          <description>LCZ696 200 mg, given as a single oral dose</description>
        </group>
        <group group_id="P3">
          <title>Healthy Volunteers (Mild HI Matched)</title>
          <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
        </group>
        <group group_id="P4">
          <title>Healthy Volunteers (Moderate HI Matched)</title>
          <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants With Mild Hepatic Impairment (HI)</title>
          <description>LCZ696 200 mg, given as a single oral dose</description>
        </group>
        <group group_id="B2">
          <title>Participants With Moderate Hepatic Impairment (HI)</title>
          <description>LCZ696 200 mg, given as a single oral dose</description>
        </group>
        <group group_id="B3">
          <title>Healthy Volunteers (Mild HI Matched)</title>
          <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
        </group>
        <group group_id="B4">
          <title>Healthy Volunteers (Moderate HI Matched)</title>
          <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="7.92"/>
                    <measurement group_id="B2" value="57.9" spread="11.67"/>
                    <measurement group_id="B3" value="58.9" spread="8.68"/>
                    <measurement group_id="B4" value="60.3" spread="11.21"/>
                    <measurement group_id="B5" value="59.0" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</title>
        <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
        <time_frame>From pre-dose on Day 1 until 96h post-dose (Day 5)</time_frame>
        <population>PK analysis set: The PK analysis set included all subjects with at least one available, valid (i.e. not flagged for exclusion) PK concentration measurement, who received any study drug, and experienced no protocol deviations with relevant impact on PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Mild Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers (Mild HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers (Moderate HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</title>
          <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
          <population>PK analysis set: The PK analysis set included all subjects with at least one available, valid (i.e. not flagged for exclusion) PK concentration measurement, who received any study drug, and experienced no protocol deviations with relevant impact on PK data.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2540" spread="1010"/>
                    <measurement group_id="O2" value="6200" spread="2970"/>
                    <measurement group_id="O3" value="1580" spread="390"/>
                    <measurement group_id="O4" value="1740" spread="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118000" spread="37000"/>
                    <measurement group_id="O2" value="173000" spread="99900"/>
                    <measurement group_id="O3" value="77900" spread="14700"/>
                    <measurement group_id="O4" value="83100" spread="14700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valsartan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28500" spread="16900"/>
                    <measurement group_id="O2" value="63800" spread="48700"/>
                    <measurement group_id="O3" value="21600" spread="5980"/>
                    <measurement group_id="O4" value="25300" spread="11800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUCinf)] of LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</title>
        <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
        <time_frame>From pre-dose on Day 1 until 96h post-dose (Day 5)</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Mild Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers (Mild HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers (Moderate HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUCinf)] of LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</title>
          <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
          <population>PK analysis set</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2540" spread="1010"/>
                    <measurement group_id="O2" value="6200" spread="2980"/>
                    <measurement group_id="O3" value="1590" spread="390"/>
                    <measurement group_id="O4" value="1740" spread="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121000" spread="41000"/>
                    <measurement group_id="O2" value="187000" spread="124000"/>
                    <measurement group_id="O3" value="78500" spread="14700"/>
                    <measurement group_id="O4" value="84100" spread="14800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valsartan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28800" spread="16900"/>
                    <measurement group_id="O2" value="65600" spread="50100"/>
                    <measurement group_id="O3" value="21900" spread="5950"/>
                    <measurement group_id="O4" value="26500" spread="12400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) for LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</title>
        <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
        <time_frame>From pre-dose on Day 1 until 96h post-dose (Day 5)</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Mild Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers (Mild HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers (Moderate HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for LCZ696 Analytes (AHU377, LBQ657, and Valsartan)</title>
          <description>Blood samples were taken on Day 1 (treatment day) within 60 minutes prior to dosing, then, 0.5,1,1.5,2,3,4,6,8,12 hours after the dosing and on Days 2, 3, 4 and 5 post dosing</description>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2530" spread="1400"/>
                    <measurement group_id="O2" value="4430" spread="1760"/>
                    <measurement group_id="O3" value="1510" spread="585"/>
                    <measurement group_id="O4" value="1410" spread="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7730" spread="1470"/>
                    <measurement group_id="O2" value="6690" spread="917"/>
                    <measurement group_id="O3" value="7450" spread="1320"/>
                    <measurement group_id="O4" value="6770" spread="1710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valsartan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4000" spread="2310"/>
                    <measurement group_id="O2" value="4180" spread="2340"/>
                    <measurement group_id="O3" value="3880" spread="1490"/>
                    <measurement group_id="O4" value="3730" spread="1540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Serious Adverse Events and Death</title>
        <description>Adverse events, serious adverse events and death were monitored from screening to end of study</description>
        <time_frame>From the screening visit until Day 5</time_frame>
        <population>Safety set: The safety set includes all participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Mild Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Hepatic Impairment (HI)</title>
            <description>LCZ696 200 mg, given as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers (Mild HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteers (Moderate HI Matched)</title>
            <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events, Serious Adverse Events and Death</title>
          <description>Adverse events, serious adverse events and death were monitored from screening to end of study</description>
          <population>Safety set: The safety set includes all participants who received study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (serious and non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Moderate Hepatic Impaired Patients</title>
          <description>Moderate hepatic impaired patients</description>
        </group>
        <group group_id="E2">
          <title>Healthy Volunteers (Mild HI Matched)</title>
          <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 1</description>
        </group>
        <group group_id="E3">
          <title>Healthy Volunteers (Moderate HI Matched)</title>
          <description>LCZ696 200 mg, given as a single oral dose. Each healthy volunteer matched in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in group 2</description>
        </group>
        <group group_id="E4">
          <title>Participants With Mild Hepatic Impairment (HI)</title>
          <description>LCZ696 200 mg, given as a single oral dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

